ICP-B208

ICP-B208 is an orally bioavailable, potent, and selective estrogen receptor degrader (SERD) being developed by InnoCare Pharma. It is specifically designed for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The molecule acts by binding to the estrogen receptor (ER), which induces a conformational change that leads to the receptor's ubiquitination and subsequent degradation via the proteasome. By reducing the cellular levels of the estrogen receptor, ICP-B208 effectively inhibits estrogen-dependent gene transcription and tumor cell proliferation. As a next-generation oral SERD, it aims to overcome resistance to traditional endocrine therapies, such as aromatase inhibitors, and provides a more convenient administration route compared to first-generation injectable SERDs like fulvestrant.